. 2020 Apr 20;21(3):e42. doi: 10.4142/jvs.2020.21.e42

Table 4. Veterinary clinical stem cell trials in gastrointestinal disease.

Disease	Cell therapy	No. of dogs	Control	Evaluation periods/effects	Ref.
Inflammatory bowel disease	Allogeneic adipose-derived MSCs; IV; 2 × 10⁷ cells/kg	11 dogs in stem cell group	No	At 6 weeks; the dogs were well tolerated and given clinical benefits.	[95,96]
Inflammatory bowel disease	Allogeneic adipose-derived MSCs; IV; 2 × 10⁷ cells/kg	11 dogs in stem cell group	No	At pre-treatment and between 90 and 120 days post-treatment; endoscopic remission in 4 dogs and histological remission was not achieved	[95,96]
Anal furunculosis	hESC-derived MSCs; intra-lesional injection within the dermis and subcutaneous tissue around the perianal fistulas; 2 × 10⁷ cells	6 dogs in stem cell group	No	At 7, 30, 60, 90, 180 days; the safety and therapeutic potential of hESC-MSCs were revealed.	[100]
FCGS	Allogeneic AD-fMSCs; IV; 20 × 10⁶ cells, 2 times, 1 month apart	7 cats in stem cell group	No	At 1 month, 3 months, and 6 months; clinical improvement and resolution in 4/7 cats; cured ~12–20 months	[102]
FCGS	Autologous AD-fMSCs; IV; 20 × 10⁶ cells, 2 times, 1 month apart	7 cats in stem cell group	No	At 1 month, 3 months, and 6 months; clinical improvement and resolution in 5/7 cats; cured ~3–9 months	[103]
Feline chronic enteropathy	Allogeneic AD-fMSCs; IV; 2 × 10⁶ cells/kg, 2 times, 2 weeks apart	7 cats in stem cell group; 4 cats in control group	Yes	At 2 weeks and 1 to 2 months; significant improvement or complete resolution of clinical signs in 5/7 cats	[101]

hESC, human embryonic stem cell; FCGS, feline chronic gingivostomatitis; MSC, mesenchymal stem cell; IV, intravenous; AD-fMSC, adipose tissue-derived feline mesenchymal stem cells.